[1] ETTINGER DS, WOOD DE, AISNER DL, et al. Non-small cell lung cancer, version 5.2017, nccn clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(4): 504. doi: 10.6004/jnccn.2017.0050
[2] EISENHAUER EA, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228. doi: 10.1016/j.ejca.2008.10.026
[3] FAEHLING M, ACHENBACH J, STAIB P, et al. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer(NSCLC)[J]. J Cancer Res Clin Oncol, 2018, 144(7): 1375. doi: 10.1007/s00432-018-2649-x
[4] LIU MH, ZHANG HY, LI Y, et al. HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer[J]. Cancer Sci, 2018, 109(9): 2717. doi: 10.1111/cas.13745
[5] LEONETTI A, ASSARAF YG, VELTSISTA PD, et al. Micrornas as a drug resistance mechanism to targeted therapies in egfr-mutated NSCSLC: Current implications and future directions[J]. Drug Resist Updat, 2019, 42: 1. doi: 10.1016/j.drup.2018.11.002
[6] LIM SM, SYN NL, CHO BC, et al. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies[J]. Cancer Treat Rev, 2018, 65: 1. doi: 10.1016/j.ctrv.2018.02.006
[7] LIN B, SONG X, YANG D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654: 77. doi: 10.1016/j.gene.2018.02.026
[8] SHEN G, ZHENG F, REN D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018, 11(1): 120. doi: 10.1186/s13045-018-0664-7
[9] TAURIN S, YANG CH, REYES M, et al. Endomemai cancers harboring mutated fibroblast growth factor receplor 2 protein are suocessfully treated witll a new smaIl tyrosine kinase inhibitor in an onhotopic mouse model[J]. Int J Gynecol cancer, 2018, 28(1): 152. doi: 10.1097/IGC.0000000000001129
[10] LUSH RM, MCCUNE JS, TETTEH L, et al. The absolute bioavailability of oral vinorelbine in patients with solid tumors[J]. Cancer Chemother Pharnacol, 2005, 56(6): 578. doi: 10.1007/s00280-005-1025-0
[11] 潘跃银, 郝吉庆, 顾康生, 等. 国产长春瑞滨软胶囊的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2004, 9(4): 376. doi: 10.3969/j.issn.1009-0460.2004.04.013
[12] HAN B, LI K, WANG Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11): 1625.
[13] WANG L, HE Z, YANG S, et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer(NSCLC): a subgroup analysis of ALTER0303 trial[J]. Transl Lung Cancer Res, 2019, 8(5): 575. doi: 10.21037/tlcr.2019.09.21
[14] 刘楠, 吴秀伟, 李烦繁, 等, 安罗替尼三线及以上治疗晚期非小细胞肺癌近期疗效及生命质量分析[J]. 国际肿瘤学杂志, 2019, 46(3): 147. doi: 10.3760/cma.j.issn.1673-422X.2019.03.004
[15] 孟令新, 曾琴琴, 孟芹, 等. 安罗替尼与贝伐珠单抗分别联合紫杉醇加卡铂治疗晚期肺腺癌的临床效果[J]. 中国医药, 2019, 14(8): 1164. doi: 10.3760/j.issn.1673-4777.2019.08.011
[16] 皇甫娟, 李文永, 张慧辉. 安罗替尼胶囊治疗晚期非小细胞肺癌对患者VEGF水平及生存期的影响[J]. 实用癌症杂志, 2020, 3(35): 360.
[17] CHENG JD, CHAI LX, ZHAO ZP, et al. Effificacy and safety of anlotinib for patients with advanced nsclc who progressed after standard regimens and the preliminary analysis of an effificacy predictor[J]. Cancer Manag Res, 2020, 12: 5641. doi: 10.2147/CMAR.S253366
[18] 金振兴, 杜秀平. 盐酸安罗替尼治疗晚期非小细胞肺癌的临床观察[J]. 临床与病理杂志, 2020, 40(4): 911.
[19] SI X, ZHANG L, WANG H, et al. Quality of life results from a randomized, placebo-controlled, multi-center phase Ⅲ trial of anlotinib in patients with advanced non-small cell lung cancer[J]. Lung Cancer, 2018, 122: 32. doi: 10.1016/j.lungcan.2018.05.013
[20] ZHANG C, KONG FW, WU WB, et al. First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature[J]. Medicine(Baltimore), 2020, 99(36): e22128.
[21] FANG S, CHENG W, ZHANG M, et al. Association of TP53 mutation with response to anlotinib treatment in advanced non-small cell lung cancer[J]. Onco Targets Ther, 2020, 13: 6645. doi: 10.2147/OTT.S257052